"New quality productivity" is a hot topic this year. This year's government work report proposes to actively cultivate emerging and future industries, including accelerating the development of cutting-edge emerging hydrogen energy, new materials, innovative drugs and other industries, and actively building new growth engines such as biological manufacturing, commercial aerospace, and low altitude economy.

As an important field of cultivating new productive forces, the development potential of the biopharmaceutical industry is enormous. What is the significance of the formation of new productive forces for the pharmaceutical industry? Regarding relevant issues, Ke Xiao, a representative of the Sichuan Provincial People's Congress, Vice President of the Chinese Society of Traditional Chinese Medicine, and President of Kanghong Pharmaceutical, gave an interview to our reporter.

Strategic emerging industries and future industries are the main battlefields for developing new quality productivity. The biopharmaceutical industry is not only an important component of the country's strategic emerging industries, but also a key area for future industrial layout. At present, China's biopharmaceutical industry has gone through a process from "nothing" to "existence", and is currently undergoing a process from "existence" to "excellence". With the help of a series of policies and new technologies, a complete biopharmaceutical industry chain system has been established, and its large-scale production capacity ranks among the top in the world. The number of innovative drugs has also entered the second tier in the world, which highlights the trend of China's transformation from a pharmaceutical producing country to a pharmaceutical powerhouse.

From the demand side, there is still a huge unmet clinical demand in China. With the intensification of population aging, the treatment of chronic diseases will constitute a vast application space for enterprises to develop new quality productivity. From the perspective of enterprises, they should continuously cultivate their own innovation and research and development capabilities. In the new wave of technological change, innovation should be the key to continuously breaking through development bottlenecks. At the same time, from the perspective of industrial green development, the application of new quality productivity at the level of innovative drugs can improve production efficiency, reduce production energy consumption, and improve product quality, which is the current direction for the development.

Strengthening China's biopharmaceutical innovation capabilities requires the concerted efforts of the entire industry chain. At present, China's biopharmaceutical industry has achieved phased progress, but there are still many areas that need to be improved, such as the source innovation of new drug research and development, the high degree of homogenization of pharmaceutical innovation, and the low conversion rate of pharmaceutical technology achievements. To promote the high-quality development of China's biopharmaceutical industry, it is necessary to establish an innovation ecosystem of government, universities, research institutions, and pharmaceutical enterprises, further strengthen basic research and intellectual property protection, reduce homogeneous competition among enterprises.